Exelixis Clinical Site #3

Nashville, Tennessee 37203

2 studies enrolling now · 4 studies all time

What they study most

Advanced Solid Tumor, Cervical Cancer, Clear Cell Renal Cell Carcinoma (ccRCC), Colorectal Cancer (CRC), Drug-Drug Interaction (DDI), Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal SCC, Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatocellular Carcinoma (HCC), Hormone Receptor-positive Breast Cancer, Immune Sensitive Tumor

Studies at this site

• Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors — Recruiting now
• A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors — Recruiting now
• A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors — Stopped early
• Study of XB002 in Subjects With Solid Tumors (JEWEL-101) — Completed